PARP Inhibitors in the Management of Ovarian Cancer
Key Points
Key Points
- These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
- The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.
Treatment
...reatme...
...eating PARPi...
...ation 1.0Repeating PARPi therapy in the treatmen...
...agnosed Ovarian Canc...
...endation 2.0PARPi are NOT recommend...
...e – Recommendation 2.1Patients wit...
...ndation 2.2The addition of olaparib to bevaci...
...endation 2.3Inclusion of the PARPi, velipa...
...current Ovarian Cancer - Second-lin...
...d Update – Recommendat...
...monotherapy maintenance (second-line or more) ma...
Maintenance treatment with niraparib for patie...
...date – Recommendation 3.1/3.2PARPi monotherapy...
...– Recommendation 3.3PARPi monotherapy is...
...Pi in Combination...
...tion 4.0PARPi are NOT recommended for use in c...
...nt of Adverse Events...
...endation 5.0 Anemia...
...requiring a blood transfusion for symptom r...
...ients with progressive anemia may be offer...
...ndation 5.1 Neutropenia:
...Growth factor is NOT indicated for use...
...ropenia (grade 4 lasting at least 5–7 days...
...dation 5.2 Platelets:...
...topenia is most common with niraparib. Nirapa...
...iscontinue PARPi for persistent thrombocytope...
...mendation 5.3 Persistent cytopenia:...
...mmendation 5.4 Naus...
...ts will have tachyphylaxis of nausea symptoms ov...
...sistent nausea requiring daily anti-e...
...hibitors in the Management of Ovarian Cancer...
...gure 1. PARPi Use Opportunities in PARP...